Background-Bradykinin may contribute to the pathogenesis of allergic rhinitis. Like histamine, nasal challenge with bradykinin induces rhinorrhoea, nasal blockage, and plasma protein leakage. Their comparative nasal potencies have not, however, been fully elucidated. Methods-Three double blind, randomised, placebo controlled and crossover studies were undertaken to compare objectively the nasal effects of bradykinin, histamine, and vehicle. Results-Both bradykinin and histamine produced dose dependent increases in nasal airways resistance (NAR). There was no significant difference in the effects of bradykinin and histamine on NAR at any dose level. On a molar basis, however, bradykinin was 6-98 times more potent than histamine in inducing a 50% increase in NAR. Nasal challenge with bradykinin and histamine also induced significant rhinorrhoea compared with vehicle. The amount of rhinorrhoea induced by histamine was significantly greater than that induced by bradykinin at any dose level. Bradykinin and histamine induced dose dependent nasal pain and nasal itch respectively. When administered as single doses both bradykinin (1 9 ,umol) and histamine (1 9 4umol) induced significant rhinorrhoea compared with the vehicle. The volume of rhinorrhoea secretions induced by histamine was 29% greater than that induced by bradykinin. In contrast, although NAR was increased significantly more by histaamine than by the vehicle, the effect of bradykinin on NAR was significantly greater than histamine and vehicle in both magnitude and duration of effect. The incremental effect of bradykinin on lavage albumin levels was also significantly greater than both histamine and vehicle.
induced significant rhinorrhoea compared with the vehicle. The volume of rhinorrhoea secretions induced by histamine was 29% greater than that induced by bradykinin. In contrast, although NAR was increased significantly more by histaamine than by the vehicle, the effect of bradykinin on NAR was significantly greater than histamine and vehicle in both magnitude and duration of effect. The incremental effect of bradykinin on lavage albumin levels was also significantly greater than both histamine and vehicle.
Conclusions-This study shows that the nasal vascular effects of histamine are less prominent than its actions on rhinorrhoea, and that the greater obstructive effect of bradykinin than histamine on NAR may contribute to the relative lack of efficacy of H, antihistamines on nasal blockage in clinical disease.
(Thorax 1993;48:324-329) Allergic rhinitis is a common condition characterised by symptoms of nasal itch, sneezing, rhinorrhoea, and nasal blockage. As the local release of histamine has been identified in both the immediate' 2 and late3 nasal response to allergen challenge, and nasal insufflation with histamine induces nasal itch, sneeze, rhinorrhoea, and transient nasal blockage," it has been implicated in the pathophysiology of rhinitis. While the local release of histamine from activated mast cells or basophils within the nasal mucosa can explain many of the symptoms of rhinitis,4 the involvement of non-histamine mediators in this disease is suggested by the incomplete therapeutic efficacy of HI antihistamines, particularly with respect to nasal blockage.4 A prominent candidate among the non-histamine mediators for a major role in rhinitis is bradykinin, a potent vasoactive nonapeptide formed as a cleavage product from the action of plasma kallikreins on high molecular weight kininogen.
Kinin activity is present in increased amounts in nasal lavage fluid after early7 and late8 phases of nasal allergen provocation. Its activity was also found to be increased in naturally occurring seasonal allergic rhinitis8 and during natural9 and induced'0 rhinoviral colds. Nasal insufflation with bradykinin elicits many of the features of rhinitis including nasal blockage, rhinorrhoea, and increased plasma vascular leakage."'-14 As the release of kinins into nasal lavage fluid is coincidental with the onset of symptoms of rhinitis after local allergen challenge, and as these kinins are known to exhibit a range of proinflammatory actions,'5 they have also been causally implicated in the pathogenesis of allergic rhinitis.
There have been few studies directly comparing the nasal effects of bradykinin with other mediators identified in association with rhinitis, and only one study comparing the nasal effects of bradykinin and histamine has been published."3 This study did not, however, attempt to match the agonists on a molar basis and did not investigate the comparative effects of these agonists on plasma protein leakage. We have therefore undertaken a double blind, randomised study to compare the nasal effects of bradykinin and histamine by investigating their effects on nasal airways resistance (NAR), rhinorrhoea, sensory nasal symptoms of pain and itch, and plasma protein exudation.
Methods

SUBJECTS
Ten non-rhinitic (asymptomatic), non-smoking, non-atopic healthy volunteers (six men and four women) with a mean age of 27 years participated in the study. All subjects refrained from taking any form of medications for one month before and throughout the study period. None of the subjects had a history of recent upper respiratory tract infection, nasal polyps, infective rhinitis, nasal surgery, or nasal deformities, and all gave written informed consent. The study was approved by the Southampton Hospitals and University joint ethical subcommittee.
CHALLENGE SOLUTIONS
Bradykinin triacetic acid (Nova Biochem Ltd, Nottingham, UK) and histamine acid phosphate (Sigma, Poole, Dorset, UK) were dissolved in 10% ethanol in 0 9% sodium chloride and 0 9% sodium chloride respectively to produce a concentration range of 0-77, 3-85, and 7-7 mg/ml (0-73, 3-63, and 7-26 x 10-3 mol/l and 2-0, 4-0, and 8-0 mg/ml (6-5, 13-0, and 26-0 x 10-3 mol/l) respectively. These doses were chosen from previous dose-response studies.4512 For the second and third phases of the study bradykinin and histamine were dissolved in the relevant diluents to produce concentrations of 7-7 mg/ml (7-26 x 10-3 moIl) and 2-25 mg/ml (7-32 x 10-3 mol/l) respectively. The purity of the synthetic bradykinin was, confirmed by high performance liquid chromatography as described previously.'2
STUDY DESIGN
The study was conducted in three phases.
Phase 1: Dose-response study The subjects attended on three occasions at the same time of day to receive nasal challenge with incremental doses of either bradykinin (019 4umol (0-2 mg), 095 ,umol (1-0 mg), and 1 9 pmol (2-0 mg)), histamine (1-7,umol (0-52 mg), 3-4,umol (1-04mg), and 6-8 pmol (2- minute intervals until the top challenge dose had been achieved. Nasal challenge was undertaken bilaterally using a hand held pump spray delivering 0-13 ml/activation with a coefficient of variation of output of 8-4%. The spray was placed in one nostril while occluding the other and activated once during quiet inspiration. The procedure was then repeated in the opposite nostril. The doses of the agonist were equally divided between nostrils. After each challenge repeat measurements of NAR were made at 3, 5, 10, and 15 minutes and subjects recorded the nasal pain or discomfort and nasal itch on a 10 cm visual analogue scale. Rhinorrhoea was measured 45 seconds before each measurement of NAR by collecting blown secretions on preweighed tissues. The tissue towels were then immediately reweighed and the weight of secretion calculated by subtraction. The symptom of sore throat was recorded as present or absent and the number of sneezes was counted.
Phase 2: Time course study Each of the 10 subjects attended on three occasions at the same time of day. At each visit, separated by at least one week, measurements were made of baseline NAR by active posterior rhinomanometry after a 15 minute rest. Subjects then underwent nasal challenge with a single dose of bradykinin (19 ,umol) , histamine (1 9 pmol), or vehicle placebo in a double blind, randomised, crossover fashion. The dose of histamine was selected on an equimolar basis to the selected dose of bradykinin. Repeat measurements of NAR were made at 3, 5, 10, 15, 20, 25, 30, 35, and 40 minutes after the challenge and subjects recorded the nasal pain or discomfort and nasal itch on a 10 cm visual analogue scale. Rhinorrhoea was measured as described above.
Phase 3: Nasal lavage study Eight subjects (five men) attended on a further three occasions having been randomly allocated to receive nasal challenge with the same single dose of bradykinin, histamine, or vehicle in a double blind, crossover design. Subjects were instructed to tilt their heads backwards about 300 from the horizontal while in the sitting position, to hold their breath, and to refrain from swallowing. Two and a half ml of 0-9% prewarmed saline were then instilled into each nostril and after 10 seconds the subjects flexed their necks and expelled the mixture of mucus and saline into a collection vessel. Samples were immediately sieved to remove mucus plugs and stored on ice until the conclusion of the experiment and then frozen at -20°C for protein analysis. At each attendance sequential nasal lavage was performed bilaterally five times, at one minute intervals, before nasal insufflation challenge with the fifth sample which was used for baseline analysis. Repeated saline nasal lavages were performed at There were no significant differences between the baseline NAR measurements (Pa cm-3s) on any of the three challenge days (p > 0 05). Nasal challenge with incremental doses of both bradykinin and histamine induced a dose dependent increase in NAR in all 10 subjects (p < 0-001) while vehicle placebo was without significant effect (fig 1) . At analogue scale of 1, 2, and 2 cm ( fig 3B) . Maximal nasal itch was felt three minutes after the challenge. Bradykinin and vehicle were without significant effect. Eight subjects sneezed more than twice in response to histamine challenge while no such response was observed after challenge with bradykinin or vehicle. Four subjects complained of a sore throat lasting up to 15 minutes after bradykinin challenge. PHASE 2 There were no significant differences between baseline NAR measurements on any of the three challenge days (p > 0-05). Both bradykinin and histamine produced significant increases in NAR compared with the vehicle, with mean maximal percentage increments three minutes after the challenge of 88% (p < 0 001) and 25% (p < 0-05) respectively.
A
The effect of histamine was transient (less than five minutes) while the increase in NAR with bradykinin was maintained throughout the 40 minute period of observation. The AUC for the time response plot for bradykinin on NAR was significantly greater than for either histamine (p < 0.05) or the vehicle (p < 0-005). Bradykinin and histamine induced significant rhinorrhoea compared with the vehicle (p < 0-05) with median secretion weights of 376 (range 83-597) mg and 484 (range 96-1700) mg respectively. The volume of rhinorrhoea secretions induced by histamine was significantly greater than that induced by bradykinin (p < 0 05).
Bradykinin induced significant nasal pain (p < 0 05) with median values of 2-8 (range 04-7-2) cm on the visual analogue scale. Histamine, however, induced significant nasal itch with a median value of 2-2 (range 1-1-4) cm. Three subjects complained of sore throat lasting for up to 25 minutes after bradykinin challenge. Four subjects sneezed more than twice in response to histamine challenge. No such response was observed after bradykinin and vehicle nasal challenges. PHASE 3 The mean volume of nasal lavage fluid recovered was 3-2 ml (64%). There were no significant differences between the fifth baseline levels of nasal lavage albumin and total protein in the eight subjects on any of the three challenge days (fig 4) . Vehicle challenge had no significant effect on these levels (fig 4) . In contrast, both bradykinin (p < 001) and histamine (p < 0-05) challenges produced significant elevations in lavage albumin and total protein levels (fig 4) , with mean maximal levels of albumin and total protein of 193-9 and 343.3,ug/ml for bradykinin, and 122-8 and 304.4 pg/ml respectively for histamine. The albumin levels induced by bradykinin were significantly greater than those induced by histamine (p < 0-05). 
Discussion
By performing both a dose-response comparison and comparison of single, equimolar dose challenges in the same subjects, it has been possible to relate the vascular and non-vascular actions of bradykinin and histamine. This study shows that bradykinin is more potent than histamine in inducing nasal vascular changes and neurally mediated nasal pain, whereas histamine has a greater effect on neurally mediated rhinorrhoea and sneeze. Although these investigations were undertaken in healthy volunteers and it is possible that bradykinin and histamine may have differing comparative nasal effects in subjects with symptomatic allergic rhinitis, previous studies in rhinitic and normal subjects have not indicated consistent differences in the nasal response between subject groups," 1214 in contrast to the distinct disease related differences identified in asthma with inhalation challenge. 18 The investigations of both NAR and nasal lavage protein and albumin measurements in the present study has allowed appraisal of the effects of bradykinin and histamine on both the nasal capacitance vessels and the superficial fenestrated capillaries within the nose. From the dose-response study it was possible to determine the PD,0 value for both agonists. This showed that bradykinin was 6-98 times more potent than histamine on a molar basis in inducing nasal blockage. Consistent with this, single dose nasal challenge with histamine produced an increase in NAR that was significantly less than that induced by an isomolar dose of bradykinin, both in magnitude and duration, and only exceeded that of the vehicle placebo at three minutes after the challenge. This weak and transient effect of histamine on NAR supports previous findings.'9 Our study therefore identifies within the confines of our experimental setup that bradykinin is more potent than histamine on a molar basis in inducing nasal blockage. The order of potency for bradykinin and histamine in influencing nasal airflow contrasts, however, with the findings reported by Doyle et al in the only other comparative study of these agonists within the nose."3 Their study indicated that histamine, when given in incremental doses, was more potent than bradykinin in inducing nasal blockage. While this might visually appear so at the highest doses investigated in the present study (fig 1) , there was no significant difference between the two agonists at any time after the challenge. It is of interest, however, that histamine challenge has been shown to produce elevated kinin levels in nasal lavage specimens,20 and an element of nasal blockage after repeated challenge with histamine could relate to an additional action of kinins rather than the action of histamine itself. This and the methods of comparison may explain the dichotomous results of Doyle et al. 13 They compared the cumulative dose effect (mg for mg) of these agonists; the doses were not compared on an equimolar basis as in the present study and no comparative time course study using equimolar doses of bradykinin and histamine was performed. As the molecular weight of histamine is 3-45 times less than that of bradykinin, the molar dose of histamine was in fact greater than that of bradykinin and their results are thus not inconsistent with the findings presented in this paper. Furthermore, Doyle et al used average nasal conductance values at three and 10 minutes for comparison,"3 in contrast to the more global AUC or specific PD50 values used in the present study. As subjects differ in their time to peak nasal response after challenge, the selection of isolated time points for analysis may give rise to inaccuracies. The use of all time points as in AUC analysis or individual peak response with frequent measurements after challenge minimises this source of error.
In addition to the influence of agonists on nasal blockage, the comparative effect of bradykinin and histamine on plasma protein exudation was also investigated within the nose. The major change in lavage proteins after challenge was an increase in albumin, the increase being significantly greater with bradykinin than histamine ( fig 4A) . The present study therefore shows that bradykinin is more potent than histamine in inducing plasma protein leakage from the superficial mucosal vasculature, in addition to its effects on the nasal capacitance vessels. This was only quantified in a single isomolar dose challenge so no mathematical estimate of the This study therefore provides a potential explanation for the relative lack of effect of H1 antihistamines in the treatment of nasal blockage in rhinitis since bradykinin, which has been found in increased amounts in nasal lavage fluid after allergen challenge in vivo, is more potent than histamine in inducing both nasal obstruction and plasma protein exudation. The development of potent and selective fl2 receptor kinin antagonists will allow further evaluation of kinins in nasal airflow obstruction and potentially enhance the treatment of allergic rhinitis.
